Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced that Chairman & CEO Dr. Amit Kumar will participate in a Water Tower Research Fireside Chat on Tuesday, November 11, 2025 at 11:00 AM PT.

The live discussion, hosted by Robert Sassoon, will cover an overview of the company, current clinical programs, and the breast cancer vaccine Phase 1 clinical trial status. The event is open to all investors with registration via Water Tower Research.

SAN JOSE, Calif., Nov. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming Water Tower Research Fireside Chat Series taking place on Tuesday, November 11, 2025, at 11:00am PT.

The Fireside Chat wil be hosted by Robert Sassoon, Managing Director – Healthcare at Water Tower Research, and will cover several topics, including:

• Overview of the Company and its clinical programs
• Breast cancer vaccine Phase 1 clinical trial status

This event is open access for all investors to participate. Interested parties can register for the event through Water Tower Research at: https://us06web.zoom.us/webinar/register/9617621959146/WN_zLl3VvR4TRyikSX7QdSoMQ

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-participate-in-water-tower-research-fireside-chat-on-tuesday-november-11-2025-302609653.html

SOURCE Anixa Biosciences, Inc.

FAQ

When will Anixa (ANIX) present at the Water Tower Research Fireside Chat?

Anixa will present on Tuesday, November 11, 2025 at 11:00 AM PT.

Who from Anixa (ANIX) will speak at the November 11, 2025 fireside chat?

Dr. Amit Kumar, Chairman and CEO of Anixa, will participate in the fireside chat.

What topics will Anixa (ANIX) cover in the November 11, 2025 presentation?

The chat will cover an overview of the company, its clinical programs, and the breast cancer vaccine Phase 1 clinical trial status.

How can investors register for the Anixa (ANIX) November 11, 2025 webcast?

Investors can register via the Water Tower Research event registration link provided by the host.

Is the Anixa (ANIX) Water Tower Research event open to the public?

Yes, the event is described as open access for all investors to participate.

Will the Anixa (ANIX) fireside chat include clinical trial updates for the breast cancer vaccine?

Yes, the agenda specifically lists the breast cancer vaccine Phase 1 clinical trial status as a discussion topic.